Price T Rowe Associates Inc. MD Grows Position in IQVIA Holdings Inc. (NYSE:IQV)

Price T Rowe Associates Inc. MD lifted its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 7.3% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 886,948 shares of the medical research company’s stock after buying an additional 60,079 shares during the period. Price T Rowe Associates Inc. MD’s holdings in IQVIA were worth $224,301,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. AdvisorNet Financial Inc raised its holdings in shares of IQVIA by 327.6% during the 4th quarter. AdvisorNet Financial Inc now owns 124 shares of the medical research company’s stock valued at $29,000 after buying an additional 95 shares in the last quarter. Rise Advisors LLC purchased a new position in shares of IQVIA during the 1st quarter valued at about $31,000. Riverview Trust Co purchased a new position in shares of IQVIA during the 1st quarter valued at about $32,000. Covestor Ltd raised its holdings in shares of IQVIA by 45.3% during the 1st quarter. Covestor Ltd now owns 154 shares of the medical research company’s stock valued at $39,000 after buying an additional 48 shares in the last quarter. Finally, Security National Bank purchased a new position in shares of IQVIA during the 4th quarter valued at about $41,000. 89.62% of the stock is owned by hedge funds and other institutional investors.

IQVIA Trading Up 3.2 %

Shares of IQV stock traded up $7.38 during trading hours on Friday, reaching $239.67. The company’s stock had a trading volume of 1,195,238 shares, compared to its average volume of 1,420,984. The stock has a market capitalization of $43.69 billion, a P/E ratio of 32.74, a P/E/G ratio of 2.26 and a beta of 1.49. IQVIA Holdings Inc. has a one year low of $167.42 and a one year high of $261.73. The firm’s fifty day simple moving average is $220.23 and its 200 day simple moving average is $229.46. The company has a current ratio of 0.85, a quick ratio of 0.88 and a debt-to-equity ratio of 1.80.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Monday, July 22nd. The medical research company reported $2.64 earnings per share for the quarter, beating the consensus estimate of $2.57 by $0.07. IQVIA had a return on equity of 28.59% and a net margin of 9.39%. The company had revenue of $3.81 billion for the quarter, compared to analyst estimates of $3.79 billion. During the same period in the previous year, the company posted $2.22 earnings per share. The firm’s revenue was up 2.3% on a year-over-year basis. Equities research analysts expect that IQVIA Holdings Inc. will post 10.21 EPS for the current year.

Analysts Set New Price Targets

IQV has been the topic of a number of research reports. The Goldman Sachs Group initiated coverage on IQVIA in a report on Thursday, June 6th. They set a “buy” rating and a $270.00 price objective on the stock. Morgan Stanley raised their price target on IQVIA from $270.00 to $280.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 23rd. UBS Group raised their price target on IQVIA from $295.00 to $300.00 and gave the stock a “buy” rating in a research report on Tuesday, July 23rd. Robert W. Baird raised their price target on IQVIA from $235.00 to $251.00 and gave the stock a “neutral” rating in a research report on Tuesday, July 23rd. Finally, Jefferies Financial Group lowered IQVIA from a “buy” rating to a “hold” rating and reduced their price target for the stock from $266.00 to $242.00 in a research report on Wednesday. Four equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. According to MarketBeat.com, IQVIA presently has an average rating of “Moderate Buy” and an average target price of $263.56.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.